Effect of fentanyl and nalbuphine for prevention of etomidate-induced myoclonus
Open Access
- 1 January 2019
- journal article
- research article
- Published by Medknow in Anesthesia: Essays and Researches
- Vol. 13 (1) , 119-125
Abstract
Background: Etomidate is a potent intravenous inducing agent with known undesirable side effects such as myoclonus and pain on injection in nonpremedicated patients. Aims: The aim of this study is to compare the effect of fentanyl and nalbuphine in the prevention of etomidate-induced myoclonus. Settings and Design: Randomized double-blind, placebo-controlled, and prospective comparative study. Materials and Methods: A total of 120 patients were randomly allocated to one of the three groups containing 40 patients each for intravenous administration of fentanyl 2 μg/kg diluted in 10 mL normal saline (NS) (Group 1), nalbuphine 0.3 mg/kg diluted in 10 mL NS (Group 2), and only 10 mL NS (Group 3) over 10 min. All groups subsequently received 0.3 mg/kg etomidate by intravenous bolus injection over 15–20 s and were assessed for the severity of pain using Grade IV pain scale and observed for myoclonus for 2 min and graded according to clinical severity. Serum creatinine phosphokinase (CPK) levels were obtained prior and postetomidate injection. Statistical Analysis: Statistical analysis was performed by the SPSS program version 17.0 for Windows. Tests used are Shaipro–Wilk test, ANOVA, Tukey's multiple comparison test, Tamhane's T2, and the Chi-square test. For all statistical tests,P < 0.05 was considered statistically significant with 5% level of significance (α). Results: The incidence of myoclonus in Group 1 and 2 was 52.5% and 17.5%, respectively, whereas it was 92.45% in Group 3. There was no pain observed in 70%, 92.5%, and 50% of patients in Group 1, 2, and 3, respectively. There was a statistically significant difference in mean CPK level after induction among three groups (P < 0.001). Conclusion: Nalbuphine is more effective than fentanyl in the prevention of etomidate-induced myoclonus and pain with the minimum rise in CPK levels.Keywords
This publication has 27 references indexed in Scilit:
- Efficacy and Safety of Opioids for the Prevention of Etomidate-Induced Myoclonus: A Meta-AnalysisAmerican Journal of Therapeutics, 2018
- Propofol decreases etomidate-related myoclonus in gastroscopyMedicine, 2017
- Comparison of the Effects of Low-Dose Midazolam, Magnesium Sulfate, Remifentanil and Low-Dose Etomidate on Prevention of Etomidate-Induced Myoclonus in Orthopedic SurgeriesAnesthesiology and Pain Medicine, 2016
- Prevention of etomidate-induced myoclonus during anesthetic induction by pretreatment with dexmedetomidineBrazilian Journal of Medical and Biological Research, 2015
- Priming with atracurium efficiently suppresses etomidate-induced myoclonusActa Anaesthesiologica Taiwanica, 2013
- Pretreatment of rocuronium reduces the frequency and severity of etomidate-induced myoclonusJournal of Clinical Anesthesia, 2008
- Low-Dose Intravenous Midazolam Reduces Etomidate-Induced Myoclonus: A Prospective, Randomized Study in Patients Undergoing Elective CardioversionAnesthesia & Analgesia, 2007
- Intravenous Etomidate for Procedural Sedation in Emergency Department PatientsAcademic Emergency Medicine, 2001
- Reducing Myoclonus after EtomidateAnesthesiology, 1999
- A comparison of etomidate and thiopental anesthesia for cardioversionJournal of Cardiothoracic and Vascular Anesthesia, 1991